Vgenomics is dedicated to addressing the global challenge of rare diseases, which affect over 350 million people worldwide, with a significant portion being children. The company focuses on developing advanced diagnostic solutions, including a comprehensive blood test capable of diagnosing more than 100 rare diseases. This initiative aims to reduce the average diagnostic time, which currently stands at seven years, thereby facilitating earlier intervention and improved patient outcomes. Vgenomics also emphasizes the importance of genomic sequencing in pediatric and neonatal care, providing specialized services to healthcare professionals to enhance the health of their youngest patients.

In addition to diagnostics, Vgenomics is committed to advancing therapeutic solutions for rare diseases. The company is working on proprietary tools designed to expedite the development of treatments, aiming to shorten the typical 10 to 15-year timeline to just 3 to 5 years. Their research team, comprised of experts with extensive backgrounds in genomics and bioinformatics, collaborates with industry leaders to innovate in the field of rare disease management. By leveraging cutting-edge technologies and a strong scientific foundation, Vgenomics is positioned to revolutionize the diagnosis and treatment of rare genetic disorders.

India

Vgenomics is an Indian company that aims to diagnose rare diseases with bioinformatics and artificial intelligence (AI). They are committed to addressing rare diseases and improving patient outcomes by analyzing complex genetic information. Vgenomics develops diagnostic and therapeutic solutions for inborn diseases, leveraging genomics and AI to bring novel solutions to the market for over 175 million children suffering from rare diseases.

Vgenomics

Company Details